Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc.
Your view on DYN
Overview
What the company does, where it operates, and who runs it.
About Dyne Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- John G. Cox
- Headquarters
- 1560 Trapelo Road, Waltham, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- John G. Cox
- Headquarters
- 1560 Trapelo Road, Waltham, MA, US
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.
It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Dyne Therapeutics, Inc., and the rating behind it. DYN last traded at $18.21; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Dyne Therapeutics, Inc.. Starting points for Dyne Therapeutics, Inc.: EPS -$3.14, beta 1.08 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Dyne Therapeutics, Inc.. Dyne Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Dyne Therapeutics, Inc.. Trailing twelve-month EPS for Dyne Therapeutics, Inc. stands at -$3.14. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Dyne Therapeutics, Inc.. Dyne Therapeutics, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Dyne Therapeutics, Inc. valued side by side against its closest peers. Dyne Therapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Dyne Therapeutics, Inc., and how their positions are changing. At a $3.40B market value, institutional positions materially move Dyne Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Dyne Therapeutics, Inc. executives and directors. Shares of Dyne Therapeutics, Inc. have traded between $6.36 and $31.32 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Dyne Therapeutics, Inc.. Dyne Therapeutics, Inc. is a $3.40B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Dyne Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Dyne Therapeutics, Inc.. Coverage tracks Dyne Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.